Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.59 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.59 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5222701 | 0.95 | FAAH (0.63) | FAAHALDH1A1LMNA | |
| SCHEMBL31366715 | 0.89 | FAAH (0.52) | TP53TSHRFAAHPLA2G4BS1PR2 | |
| SCHEMBL9308211 | 0.88 | FAAH (0.63) | TP53TSHRFAAHPLA2G4BS1PR2 | |
| SCHEMBL28827967 | 0.87 | FAAH (0.65) | TP53TSHRFAAHS1PR2S1PR1 | |
| SCHEMBL9307359 | 0.85 | SMN1; SMN2 (0.67) | TP53TSHRLMNA | |
| SCHEMBL9565606 | 0.84 | FAAH (0.73) | FAAH | |
| SCHEMBL15514715 | 0.82 | NPC1 (0.66) | LMNA | |
| SCHEMBL2573742 | 0.82 | NR1H4 (0.52) | FAAHPLA2G4B | |
| SCHEMBL29982783 | 0.81 | TSHR (0.54) | TP53TSHRFAAHALDH1A1LMNA | |
| SCHEMBL9819792 | 0.81 | FAAH (0.52) | TP53TSHRFAAHS1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | claimed |
| CN-119451683-A | Oligonucleotide compositions and methods thereof | 艾米利克斯制药公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| CN-118647614-A | Crystalline forms of N- (6-amino-5-methylpyridin-3-yl) -2- (benzo [ d ] thiazol-5-yl) -5-methylpiperidin-1-yl) -2-oxoacetamide, pharmaceutical compositions and methods of use | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-115322193-A | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115135765-A | Chemically modified oligonucleotides targeting bromodomain-containing protein 4(BRD4) for immunotherapy | 菲奥医药公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-2576569-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | Pharma Mar S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2231695-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | SERPINH1, ERLIN2, PTMA | TP53 2057/4885TSHR 864/4885FAAH 1483/4885 |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | TP53, XPO1, TOP2B | TP53 1/4885TSHR 3807/4885FAAH 4188/4885 |
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | TP53 1/4885TSHR 3807/4885FAAH 4188/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | TP53 1/4885TSHR 4635/4885FAAH 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.